Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Pharming announces initiation of clinical phase I/II pre-eclampsia study
Volgen
Leiden, the Netherlands – 11 June 2019 Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia. Sijmen de Vries, Chief Executive Officer of Pharming, commented: “Our strong performance in 2018 and the first quarter of 2019 has enabled us to invest in future growth through the development of our pipeline. Today, following ethics committee approval, we are initiating our first pre-eclampsia study with RUCONEST®. The first part of the study will assess safety and tolerability in a small number of patients to confirm the safety profile of RUCONEST® before proceeding to a larger patient sample. The second part of the study will involve a wider group to assess preliminary efficacy parameters as well. The results will be combined and are expected to be available in the third quarter of 2020. With no current approved therapies to treat pre-eclampsia, we look forward to treating the first patients in this study as we seek to address the very serious unmet patient need and improve the safety and outcomes of pregnant women and their unborn babies with this condition in the future.” Pre-eclampsia (PE) is a life-threatening multisystem condition in pregnancies leading to increased maternal and neonatal mortality and morbidity. 50,000 maternal deaths during pregnancy per year around the world are recorded for patients who proceed to eclampsia, while many more are caused by long-term irreversible damage to organs caused by PE. Treatments include termination of pregnancy or premature birth. Even if born safely, over half of these newborns will suffer from growth restrictions, learning difficulties or moderate to severe disabilities. Almost 2.5 million cases of PE are reported annually, with rates running at between 1% and 17% of all pregnancies in various communities and countries. Premature delivery is presently the only solution for PE, and there are no approved therapies. This is not a viable option for early PE (from week 20 of pregnancy). The main goal of therapy is therefore to prolong a safe pregnancy for PE patients as long as possible to improve the chances of a good outcome from delivery. Clinical trial designIn September 2018, Pharming filed a clinical trial application with the European Medicines Agency (EMA) to initiate the clinical development of RUCONEST® to treat and prevent pre-eclampsia (PE). As part of this process, the study was submitted to and has just been cleared by the first investigating centre’s ethics committee. A similar clinical trial application has been filed with the Therapeutic Goods Administration (TGA) in Australia where it is still subject to ethics committee clearance. The first part of the study is an open label trial to investigate tolerability and safety of treatment with RUCONEST®. Very soon, Pharming will begin recruiting a small number of patients in this part of the study in mid- to late-stage symptomatic pre-eclampsia, where women at 27 weeks’ term or later may receive RUCONEST® from their first clear symptoms of PE for the remainder of their pregnancy. Patients will be constantly monitored to ensure their safety and that of the fetus. To date, RUCONEST® has been used to treat HAE in approximately 50 pregnant HAE patients (up to 40 times during a single pregnancy), including during delivery, with no safety issue for either mother or baby detected at the time or since. The second (open label, proof of concept) part of the study (following approval by the ethics committees) is planned to include 30 patients in total recruited between two centres, of which one is in the Netherlands and one in Australia. Patients with mild to moderate pre-eclamptic symptoms at 27 to 34 weeks of pregnancy will be selected. Patients will receive only those doses of RUCONEST® already known to be safe from the first part of the study. The second part of the study will also test RUCONEST® against (historical) documented standard-of-care results in similar patients. According to key opinion leaders in pre-eclampsia, every extra day closer to an on-term delivery can make an important difference for both mother and baby. The entire study is expected to last approximately one year, depending on the rate of recruitment and the early stage safety performance. Scientific Rationale The precise causes of pre-eclampsia are not known, but abnormal or impaired spiral artery modifications between the mother and the fetus are believed to be involved, as is the complement system which is triggered when these spiral arteries come under stress, especially oxidative stress because of poor blood flow. Emerging evidence has shown that activation of the complement system following such poor placentation is implicated in the pathological processes of PE.C1 esterase inhibitor (C1INH) is a key component of the complement system and the only natural inhibitory mechanism of the system. Pregnant women and pre-eclamptic women have reduced circulating C1INH levels. Severely affected PE patients have significantly-reduced C1INH levels. It is therefore postulated that by supplying additional rhC1INH to such patients, it may be possible to slow the rate of progress of the condition and thereby reduce the level of damage that it can cause to mother and the unborn baby. The main goal of therapy is to prolong a safe pregnancy for PE patients as long as possible to improve the chances of a good outcome from delivery. RUCONEST® is also being examined for approval for the treatment of HAE in young children (2-13 years of age) and a clinical Phase I/II trial has been initiated for the treatment and prevention of pre- eclampsia.
RUCONEST® is also evaluated for various additional indications. Pharming’s technology platform includes a unique, GMP-compliant, validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods. Leads for enzyme replacement therapy (“ERT”) for Pompe and Fabry’s diseases are being optimized at present, with additional programs not involving ERT also being explored at an early stage at present. Pharming’s technology platform includes a unique, GMP-compliant, validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods. Leads for enzyme replacement therapy (“ERT”) for Pompe and Fabry’s diseases are being optimized at present, with additional programs not involving ERT also being explored at an early stage at present. Pharming has a long-term partnership with the China State Institute of Pharmaceutical Industry (“CSIPI”), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Pre-clinical development and manufacturing will take place to global standards at CSIPI and are funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.Forward-looking Statements This press release of Pharming Group N.V. and its subsidiaries (“Pharming”, the “Company” or the “Group”) may contain forward-looking statements including without limitation those regarding Pharming’s financial projections, market expectations, developments, partnerships, plans, strategies and capital expenditures. The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limit ation the effect of competitive, political and economic factors, legal claims, the Company’s ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices and the Company’s ability to identify, develop and successfully commercialize new products, markets or technologies. As a result, the Company’s actual performance, position and financial results and statements may differ materially from the plans, goals and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue, unless required by laws or regulations.
Magnesium tegen zwangerschapsvergiftiging Magnesium, intraveneus of intramusculair toegediend, halveert het risico van zwangerschapsvergiftiging, aldus een publicatie in de Lancet. Bovendien daalt de kans dat de moeder tijdens of kort na de bevalling overlijdt. De injectie kan wel voor lichte bijwerkingen zorgen, maar dit lijkt geen schadelijke effecten te hebben voor moeder of kind. Een multicenter onderzoek werd door de Magpie Trial Collaboration Group uitgevoerd, gecoördineerd door dr Lelia Duley van het Institute of Health Sciences in Oxford. Zwangere vrouwen met pre-eclampsie deden mee, een aandoening waarbij de vrouwen stuipen en krampen krijgen die levensbedreigend kunnen zijn voor moeder en kind (eclampsie). Ruim 10.000 vrouwen uit 33 landen deden aan deze studie mee. De vrouwen waren nog niet bevallen of hadden de bevalling maximaal 24 uur achter de rug. Zij hadden pre-eclampsie, oftewel een verhoogde bloeddruk die minimaal 140 over 90 mmHg, gecombineerd met proteïnurie. Deze vrouwen kregen willekeurig magnesiumsulfaat of een niet-werkzame stof intraveneus of intramusculair ingespoten en werden gevolgd totdat zij het ziekenhuis mochten verlaten. Magnesiumsulfaat verminderde de kans op zwangerschapsvergiftiging met 58% in vergelijking met de controlegroep. Dit betekent dat het aantal gevallen van eclampsie in een groep van 1.000 zwangere vrouwen met elf daalt. Daarnaast daalde het risico dat de moeder zou overlijden met vrijwel de helft van 0,4 naar 0,2%. Magnesium was niet van invloed op het aantal gevallen van kindersterfte.
ki schreef op 11 juni 2019 09:59 :
Magnesium tegen zwangerschapsvergiftiging
Magnesium, intraveneus of intramusculair toegediend, halveert het risico van zwangerschapsvergiftiging, aldus een publicatie in de Lancet. Bovendien daalt de kans dat de moeder tijdens of kort na de bevalling overlijdt. De injectie kan wel voor lichte bijwerkingen zorgen, maar dit lijkt geen schadelijke effecten te hebben voor moeder of kind. Een multicenter onderzoek werd door de Magpie Trial Collaboration Group uitgevoerd, gecoördineerd door dr Lelia Duley van het Institute of Health Sciences in Oxford. Zwangere vrouwen met pre-eclampsie deden mee, een aandoening waarbij de vrouwen stuipen en krampen krijgen die levensbedreigend kunnen zijn voor moeder en kind (eclampsie). Ruim 10.000 vrouwen uit 33 landen deden aan deze studie mee. De vrouwen waren nog niet bevallen of hadden de bevalling maximaal 24 uur achter de rug. Zij hadden pre-eclampsie, oftewel een verhoogde bloeddruk die minimaal 140 over 90 mmHg, gecombineerd met proteïnurie. Deze vrouwen kregen willekeurig magnesiumsulfaat of een niet-werkzame stof intraveneus of intramusculair ingespoten en werden gevolgd totdat zij het ziekenhuis mochten verlaten. Magnesiumsulfaat verminderde de kans op zwangerschapsvergiftiging met 58% in vergelijking met de controlegroep. Dit betekent dat het aantal gevallen van eclampsie in een groep van 1.000 zwangere vrouwen met elf daalt. Daarnaast daalde het risico dat de moeder zou overlijden met vrijwel de helft van 0,4 naar 0,2%. Magnesium was niet van invloed op het aantal gevallen van kindersterfte.
Zeer oud bericht en totaal niet actueel.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)